Jun. 17, 2012
The Swiss-based Debiopharm Group, a global biopharmaceutical conglomerate, and Ascepion Pharmaceuticals, a Chinese privately-held biopharmaceutical company, have entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126, a multikinase inhibitor currently in pre-clinical development. ASP-08126 is a potent orally available small molecule that binds and inhibits several tyrosine kinase oncogenes implicated in many aspects of cancer development including tumor growth, metastasis, and tumor angiogenesis. ASP-08126 is expected to be effective in the treatment of various solid tumors as a mono-therapeutic agent or in combination with other anti-cancer therapies.